CD44 and cancer: Recent studies have shown that cancer stem cells (CSCs) may originate from non-cancer stem cells and that ZEB1 plays a pivotal role in this process, as knockdown of ZEB1 could revert the CSC properties of prostate cancer cells such as colony-forming ability and the expression of canonical CSC markers (SOX2, CD44 and CD133) [13].